

depending upon the availability of funds. The meetings may be conducted by teleconference or videoconference at the discretion of the Designated Federal Officer. The meetings shall be open to the public, except as determined otherwise by the Secretary, or other official to whom authority has been delegated, in accordance with the guidelines under Government in the Sunshine Act, 5 U.S.C. 552b(c). Notice of all meetings shall be provided to the public in accordance with the Federal Advisory Committee Act. Meetings shall be conducted and records of the proceedings shall be kept, as required by applicable laws and departmental policies. A quorum is required for the Task Force to meet to conduct business. A quorum shall consist of a majority of the Task Force's members. When the Secretary or the Secretary's designee determines that a meeting shall be closed or partially closed to the public, in accordance with provisions of Government in the Sunshine Act, 5 U.S.C. 552b(c), then a report shall be prepared by the Designated Federal Officer that includes, at a minimum, a list of members and their business addresses, the Task Force's functions, date and place of the meeting, and a summary of the Task Force's activities and recommendations made during the fiscal year. A copy of the report shall be provided to the Department Committee Management Officer.

**Nominations:** Nominations, including self-nominations, of individuals who have the specified expertise and knowledge will be considered for appointment as members of the Task Force. A nomination should include, at a minimum, the following for each nominee: (1) A letter of nomination that clearly states the name and affiliation of the nominee, the basis for the nomination, and a statement from the nominee that indicates that the individual is willing to serve as a member of the Task Force, if selected; (2) the nominator's name, address, and daytime telephone number, and the address, telephone number, and email address of the individual being nominated; and (3) a current copy of the nominee's curriculum vitae or resume, which should be limited to no more than 10 pages.

Every effort will be made to ensure that the composition of the Task Force includes individuals from various geographic locations, including rural and underserved areas; racial and ethnic minorities; genders, and persons living with disabilities.

Individuals other than officers or employees of the United States government being considered for

appointment as members of the Task Force will be required to complete and submit a report of their financial holdings. An ethics review must be conducted to ensure that individuals appointed as members of the Task Force are not involved in any activity that may pose a potential conflict of interest for the official duties that are to be performed. This is a federal ethics requirement that must be satisfied upon entering the position and annually throughout the established term of appointment on the Task Force.

**Authority:** Section 101 of the Comprehensive Addiction and Recovery Act of 2016 (Pub. L. 114–198) authorizes establishment of the Pain Management Best Practices Inter-Agency Task Force. The Task Force will be governed by provisions of the Federal Advisory Committee Act, Public Law 92–463, as amended (5 U.S.C. App. 2), which sets forth standards for the formation and use of Federal advisory committees.

Dated: August 21, 2017.

**Donald Wright,**

*Acting Assistant Secretary for Health.*

[FR Doc. 2017–18182 Filed 8–25–17; 8:45 am]

**BILLING CODE 4150–28–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Document Identifier: OS–0990–new]

### Agency Information Collection Request. 30-Day Public Comment Request

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** In compliance with the requirement of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, is publishing the following summary of a proposed collection for public comment.

**DATES:** Comments on the ICR must be received on or before September 27, 2017.

**ADDRESSES:** Submit your comments to [OIRA\\_submission@omb.eop.gov](mailto:OIRA_submission@omb.eop.gov) or via facsimile to (202) 395–5806.

**FOR FURTHER INFORMATION CONTACT:** Sherrette Funn, [Sherrette.Funn@hhs.gov](mailto:Sherrette.Funn@hhs.gov) or (202) 795–7714. When submitting comments or requesting information, please include the document identifier 0990-New-30D and project title for reference

**SUPPLEMENTARY INFORMATION:** Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of

information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

**Project Title:** Assessment of the Impact of Energy Development on the Behavioral Health of Women in Western North Dakota and Eastern Montana, The Region VIII Office of the Assistant Secretary for Health (OASH), Office on Women's Health (OWH).

**Abstract:** The Office on Women's Health (OWH) in the Office of the Assistant Secretary for Health, U.S. Department of Health and Human Services (HHS) is requesting approval from the Office of Management and Budget (OMB) for a new data collection for the Assessment of the Impact of Energy Development on the Behavioral Health of Women in Western North Dakota and Eastern Montana. Its mission is to provide national leadership and coordination to improve the health of women and girls through policy, education and model programs. Region VIII OASH/OWH is interested in improving women's behavioral health associated with the impact of energy development through gender based data collection and analysis. The discovery and subsequent development of the Parshall Oil Field within the Bakken region of Western North Dakota has led to significant economic opportunity and population growth in the region (Eastern Montana and Western North Dakota). Rapid population growth has many intended and unintended consequences, both positive and negative, on the social and economic environment of the region and, consequently, the population's health and well-being.

**Need and Proposed Use of the Information:** There are well-documented environmental health issues associated with oil and gas development, including air, water, soil, noise, and light pollution. However, there are additional social, physical and mental health effects that are less well documented. Current research is very limited, but preliminary evidence suggests that women have unmet behavioral health needs due in part to the energy development and population surge in region. These data will ultimately be used to understand the impact of energy development on the behavioral health of women in Eastern Montana and Western North Dakota.

There will be a final report that is thematically organized and describes key findings and strategic recommendations for Region VIII OASH/OWH to consider supporting future evidence-based program development and implementation,

policy recommendations, and future research.

*Likely Respondents:* Data for this assessment will be collected through three mechanisms—a survey of women living in the assessment geography, focus groups with a cross-section of women and other key groups living in

the assessment geography, key leaders and stakeholders across a variety of governmental and non-governmental sectors.

The total annual burden hours estimated for this ICR are summarized in the table below.

#### TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS

| Form name              | Number of respondents | Number of responses per respondent | Average burden per response (in hours) | Total burden hours |
|------------------------|-----------------------|------------------------------------|----------------------------------------|--------------------|
| Community Survey ..... | 500                   | 1                                  | 15/60                                  | 125                |
| Focus Groups .....     | 240                   | 1                                  | 90/60                                  | 360                |
| Interviews .....       | 40                    | 1                                  | 60/60                                  | 40                 |
| Total .....            | 780                   | 1                                  | 40.4/60                                | 525                |

**Terry S. Clark,**

*Asst Information Collection Clearance Officer.*

[FR Doc. 2017–18117 Filed 8–25–17; 8:45 am]

**BILLING CODE 4150–33–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel NIAID Peer Review Meeting.

*Date:* September 20–21, 2017.

*Time:* 12:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892, (Telephone Conference Call).

*Contact Person:* Kelly Y. Poe, Ph.D., Scientific Review Program, Division of Extramural Activities, Room 3F40B, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–5036, [poeky@mail.nih.gov](mailto:poeky@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: August 22, 2017.

**Natasha M. Copeland,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2017–18121 Filed 8–25–17; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

#### FOR FURTHER INFORMATION CONTACT:

Chris Kornak, 240–627–3705, [Chris.Kornak@nih.gov](mailto:Chris.Kornak@nih.gov). Licensing information and copies of the U.S. patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel.

301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.

**SUPPLEMENTARY INFORMATION:** Technology description follows.

#### HIV Targets CD62L on Central Memory T Cells Through Viral Envelope Glycans for Adhesion and Induces Selectin Shedding for Viral Release

##### Description of Technology

Despite the success of anti-retroviral therapy in controlling HIV in infected individuals, treatment is less effective at eliminating HIV viral reservoirs. The nature of HIV reservoirs and the factors controlling their size and release are a major research focus for achieving a cure for HIV/AIDS.

NIAID researchers have identified L-selectin/CD62L as a new target for treating HIV by inhibiting viral release from infected cells. They found that shedding of CD62L on T cells is required for the efficient release of HIV virus from infected cells. Further, they have shown that inhibition of CD62L shedding dramatically reduced HIV–1 infection and viral release from both viremic and aviremic CD4+ T cells. Therefore, inhibitors for CD62L sheddase can function as an anti-HIV treatment that may be effective alone or in combination with existing therapeutics.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

##### Potential Commercial Applications

- New target for HIV therapeutic development.